DonCorleone77
Posted - 7 minutes ago
$HOOK $GILD Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program In a regulatory filing on Wednesday, Hookipa Pharma (HOOK) announced that on November 18, the company approved a plan to continue to improve its cost structure and operating efficiency, which includes a reduction in the company's workforce by approximately 80% of the company's then-current employee base. The company expects to begin the implementation of the Restructuring Plan in the fourth quarter of 2024 and expects the Restructuring Plan to be substantially completed by the end of the first half of 2025. In connection with the Restructuring Plan, in an effort to rebalance the company's cost structure in alignment with the company's strategic refocus and development of its oncology portfolio, the company also announced that it will pause clinical development in its eseba-vec program for the treatment of Human Papillomavirus 16-positive head and neck cancers, including an early termination of the company's ongoing Phase 1/2 clinical trial for the treatment of HPV16+ cancers. The company's early termination of its ongoing Phase 1/2 clinical trial for the treatment of HPV16+ is not due to lack of efficacy or adverse safety profiles. While the company will continue to seek partnering opportunities for the eseba-vec program, the company will focus primarily on progressing the phase 1-ready HB-700 program for the treatment of KRAS mutant cancers. In April 2024, the Company received Investigational New Drug clearance from the U.S. Food and Drug Administration for HB-700 for the treatment of KRAS mutated cancers, including, lung, colorectal and pancreatic cancers. Notwithstanding the company's Restructuring Plan and the immediate pause of the eseba-vec program, the company continues to enroll patients in its ongoing Phase 1b clinical trial related to its Human Immunodeficiency Virus program, HB-500, being developed in a partnership with Gilead Sciences (GILD). In addition, the company continues to support its Hepatitis B program, HB-400, which is also being developed in a partnership with Gilead.
Idvst8
Posted - 14 hours ago
$GILD - 8k
JimiJoJeeter
Posted - 14 hours ago
@MustaT The problem is one of effective management. Unfortunately, Macrae screwed up big time. After the $GILD (Kite Pharma) deal, they had half a billion cash and about 90 million shares float. The company should have been sold then. Macrae instead bought a Treg company, expanding their footprint in Europe. He also keased a larger building, along with swelling the employee count. His profligate spending put them exactly where one would expect them to be. Now, we know some things don't pan out. Like the MPS editing trial. That's understandable. But that's planning. The bottom line is that he spent too much and cut too late. That equals bad fiscal management.... IMHO
ThomasTrainTrader
Posted - 16 hours ago
$KYTX This is incredible $KYTX and $GILD dream team
ThomasTrainTrader
Posted - 17 hours ago
@Magic8BallResponse Kyverna has enough funding right now to bring a handful of indications to the end of Phase 3. This is not even considering a $250 million injection they are poised to get from $GILD. Gilead has had a strong partnership with Kyverna and will likely provide the additional $250 mil milestone payment especially since the leadership team now is dominated by $GILD/Kite people who have deep ties to the company
ThomasTrainTrader
Posted - 17 hours ago
$KYTX Let's gooooooo another HC Wainwright downgrade who could've guessed. Keep in mind the reasoning is "potentially dilutive shares outstanding" when Kyverna has $321 million in cash and additional support from $GILD. Also keep in mind this guy has a $25 rating on $CABA when it has far less data and also 1/3 of the funding of Kyverna meaning it will definitely have to raise and dillute https://www.tipranks.com/news/the-fly/kyverna-therapeutics-price-target-lowered-to-6-from-7-at-h-c-wainwright
wilno
Posted - 20 hours ago
$GILD 75 by MAHA!
DefenseMania
Posted - 20 hours ago
$GILD get in RCUS before GILD acquires them $14.45 A STEAL !!!!!!’
$AZN $BMY $LLY $MRK
7Billiards
Posted - 21 hours ago
$ALT $GILD $MRK $NVO $PFE class leading MASH data 50Bn TAM
GreenEnergy2022
Posted - 21 hours ago
$ALT Class leading MASH data, 500 mcap, MASH ph2 soon going into phs3. Madrigal & Viking with inferior data. "Pemvidutide reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after 12 weeks of treatment." $NVO $GILD $MRK $PFE
DomLuminous
Posted - 1 day ago
$GILD 75 is the number!
wilno
Posted - 2 days ago
$GILD those who do not understand the power of 75 are like a kite tossed by storm.
DividendsAtValue
Posted - 2 days ago
@Easymoney48 @VQ350GeTsome Yup. Today, just before the close I added to $PFE as well. Great price with almost 7% and a huge pipeline. I'll e collecting from it for years. Brings pharma to nearly 20% of my portfolio. At 20% no more pharma for me. I'll be selling a position in $GILD...
For some reason, I get a calm, almost euphoric feeling from investing in pharma.
DividendsAtValue
Posted - 2 days ago
$PFE Just added here, but saved some cash allocated for $PFE hoping to add more at an even lower price...
Let's just say I like drug stocks...
Long $ABBV $GILD $PFE
erevnon
Posted - 2 days ago
RBC Capital maintains Gilead Sciences $GILD at Sector Perform and raises the price target from $81 to https://marketsblock.com/stock-upgrades-and-downgrades/
DividendsAtValue
Posted - 2 days ago
@MakingLunchMoney Someone did a chart prediction low as $22.00, that said I think this is an excellent place to buy. I added Friday and intend to add more. Am getting out of $GILD and putting that into $PFE.
Long $ABBV $$PFE
ripztrip
Posted - 2 days ago
$KYTX All patients at six months of follow-up after treatment at the target dose continue to display sustained efficacy and durability across numerous key clinical measures. “As our KYV-101 clinical datasets mature, we are increasingly able to focus on the right patients, treated at the right dose, with the right protocol. We are excited to share these new data, which continue to reinforce KYV-101’s potential for durable and life-changing outcomes in lupus nephritis patients, including those with high chronicity and disease severity,” said Warner Biddle, Chief Executive Officer at Kyverna $CABA $RNAC $GILD $PFE
wilno
Posted - 2 days ago
$GILD 75 by eoy! MAHA!
Thestocktraderhubzee
Posted - 2 days ago
$GILD RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $84
ripztrip
Posted - 2 days ago
$KYTX looking good pre market. some news/PR not posted yet? $CABA $RNAC $GILD $PFE
DonCorleone77
Posted - 3 days ago
$IDYA $GILD Ideaya Biosciences appoints Stu Dorman as chief commercial officer Ideaya (IDYA) announced the appointment of Stu Dorman as chief commercial officer. Dorman has over 20 years of oncology and hematology experience. Prior to joining Ideaya, Dorman was the VP, U.S. oncology business unit head at Gilead Science (GILD).
DividendsAtValue
Posted - 3 days ago
@DinoMcnuggets @Johnny_Lever @risingphoenix2024 Not my way. I very rarely trade. I'm getting out of $GILD to consolidate my pharma. I'll put the $GILD money into $PFE and collect the dividend. If I have a good stock giving me a flow of dividend income (currently reinvested) I won't sell. I'll hold.
DividendsAtValue
Posted - 3 days ago
@DinoMcnuggets @Johnny_Lever @risingphoenix2024 Well unlike you I don't have limitless money. I need to sell my $GILD to raise capital to buy this. I can wait a bit to see if I can get more shares of $PFE for the same amount of money. My about40 stocks, most listed in my profile. I am only focused on buying three at current prices. $PFE is one of them. In the mean time, take a chill pill.
ripztrip
Posted - 3 days ago
$KYTX CASH on balance sheet $321 MILLION --- Market Cap $187 Million --- please find me any public company that has that dynamic $RNAC $CABA $NTLA $GILD I will be waiting with bated breath...
ripztrip
Posted - 3 days ago
$KYTX Presentation tomorrow $CABA $RNAC $GILD
DividendsAtValue
Posted - 4 days ago
@DumbNDumper Well, I would have to really fall a lot for me to get more because it's already 13% of my portfolio and with an avg pp sh of $80, I probably be DCAing up, and I don't like to do that, but if it fell substantially I might I've been adding to a smaller portfolio position in $PFE because it has a hefty yeild, around 6%! I plan on selling my position in $GILD and putting the money into $PFE. That would leave my pharma pretty much in two companies, And give me a substantial flow of additional dividends!
DividendsAtValue
Posted - 5 days ago
@Jeffg1981 The lower it goes, the more I want. I'll be exiting my position in $GILD and putting most of that into $PFE too!
DividendsAtValue
Posted - 5 days ago
@mathgenius Panic? Are you kidding? I'm delighted (not at the appointment of RFK, at the opportunity). This will push prices down and allow us to buy at great discounts.
$ABBV is my second largest position.
I added to $PFE this afternoon.
Long $ABBV $GILD $MNKD $PFE
Stocksrunner
Posted - 5 days ago
$GILD gilead unveils promising long-term data on seladelpar for liver disease. expect some upside if this continues to show positive results in the trials.
